Subscribe

Web Exclusives: Value-Based Care - June 2017

New Orleans, LA— The oral investigational agent ozanimod, which is from the same drug class as fingolimod (Gilenya), may be as effective as fingolimod, with fewer safety concerns, for the treatment of patients with relapsing multiple sclerosis (MS), reported Brett E. Skolnick, PhD, Receptos, San Diego, CA, at the 2017 Consortium of Multiple Sclerosis Centers annual meeting. Dr Skolnick stepped in for the lead investigator Giancarlo Comi, MD, Vita-Salute San Raffaele University, Neurology, Milan, Italy, who was unable to attend the meeting.

Results 1 - 1 of 1
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology